Table 1

Baseline characteristics of the patients of the treat-to-target (T2T) and usual care (UC) groups
T2T (n=261) UC (n=213) UC from 2006 (n=69)
Age, mean ± SD years 57.9 ± 13.8 56.6 ±13.4 53.9 ±13.0†
Female sex, n (%) 161 (61.7) 132 (62.0) 43 (62.3)
RF positive, n (%) 178 (68.2) 147/211 (69.7) 48/69 (69.6)
DAS28, mean ± SD 5.0 ± 1.1 4.8 ± 1.2† 4.8 ± 1.3
No. of swollen joints (28 assessed), median (IQR) 8 (5–12) 9 (6–13)† 8 (5–12)
No. of tender joints (28 assessed), median (IQR) 5 (2–9) 4 (2–9) 4 (1–9)
ESR, median (IQR) mm/hour 28.0 (15.5-42.0) 26.0 (12.0-39.0) 29.0 (17.0-43.5)
CRP, median (IQR) mg/litre 14.0 (5.0-34.5) 6.7 (0.0-27.8)† 10.0 (0.0-34.3)
VAS general health, mean ± SD (0–100) 52.9 ± 22.6 45.7 ± 23.0† 42.9 ± 24.4†
VAS pain, mean ± SD (0–100) 51.2 ± 21.9 44.9 ± 23.2† 46.5 ± 23.9
HAQ score, median (IQR) 1.1 (0.6-1.5) (n=244) 0.9 (0.5-1.4) (n=151)† 0.9 (0.4-1.4) (n=52)†

CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IQR, interquartile range; RF, rheumatoid factor; SD, standard deviation; VAS, visual analog scale.

† P < 0.05 for differences between groups (T2T versus UC).

Vermeer et al.

Vermeer et al. BMC Musculoskeletal Disorders 2013 14:350   doi:10.1186/1471-2474-14-350

Open Data